Compare Illumina, Inc. (ILMN) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Plby Group Inc — how do they compare? Illumina, Inc. trades at $180.13 (market cap $27.94B), while Plby Group Inc trades at $1.21 (market cap $139.87M). The key difference: Illumina, Inc. is far larger — about 199.8× Plby Group Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | PLBY | |
|---|---|---|
Market Cap | $27.94B | $139.87M |
Sector | Health | Consumer Cyclical |
52-Week High | $194.33 | $2.71 |
52-Week Low | $91.00 | $1.11 |
Enterprise Value | $29.33B | $287.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
PLBY Group trades at $1.21, up 3.42% with a market cap reflecting a P/S ratio of 1.02. The company shows improving fundamentals with five consecutive quarters of positive adjusted EBITDA and narrowing losses, though it remains unprofitable with negative ROE. Technical indicators signal bearish momentum despite neutral oscillators. Recent developments include Russell index inclusion and a strategic share repurchase program.
The outlook remains cautious due to persistent net losses and high debt levels, but operational improvements and brand repositioning offer potential upside. Key risks include execution challenges in licensing growth and competitive pressures in the leisure sector. Analyst consensus is strongly bullish with 75% buy ratings, suggesting confidence in the turnaround strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
